Yahoo Finance

IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety

In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
Monthly Prescribing Reference

Izervay Approved for Geographic Atrophy Secondary to AMD

Credit: Iveric Bio. Izervay is expected to be available in 2 to 4 weeks. The Food and Drug Administration (FDA) has approved Izervay ™ (avacincaptad pegol intravitreal solution) for the treatment of ...
Seeking Alpha

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S.
Morningstar

Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting

Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...
Medical News Today

Izervay interactions: Alcohol, medications, and other factors

Izervay (avacincaptad pegol) is a brand-name eye injection that’s prescribed for an advanced form of age-related macular degeneration. Izervay is not known to interact with other drugs. Izervay is ...